Резолюция научного совета экспертов: «Место нового анти-CD20 препарата дивозилимаб в терапии пациентов с прогрессирующей системной склеродермией (системным склерозом)»

1. Ananyeva LP, Tyurin IE, Koneva OA, Garzanova LA, Lila AM. Interstitial lung disease in systemic sclerosis (systemic scleroderma). Modern Rheumatology Journal. 2021; 15(1S):1-62 (In Russ.). doi: 10.14412/1996-7012-2021-1S-1-62

2. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): Open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2022;4(8):e546-e555. doi: 10.1016/S2665-9913(22)00131-X

3. Pereira NA, Chan KF, Lin PC, Song Z. The ‘less-is-more’ in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs. 2018;10(5):693-711. doi: 10.1080/19420862.2018.1466767

4. Boyko OV, Boyko AN, Yakovlev PA, Zinkina-Orikhan AV, Kotov SV, Linkova YN, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): Pharmacokinetics, pharmacodynamics and safety. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):87-95 (In Russ.). doi: 10.17116/jnevro201911910287